Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYNOTE-158 pembrolizumab in advanced rare solid tumors
NL-OMON53123Phase 2Recruiting
- Sponsor
- Merck & Co.
- Start
- Dec 2015
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab in anal squamous cell carcinoma (SCCA), biliary adenocarcinoma, apudoma (NET) and 9 more, sponsored by Merck & Co. Primary endpoint: Objective response rate. Started Dec 2015; status: recruiting.
02
Drugs
03
Conditions
anal squamous cell carcinoma (SCCA)biliary adenocarcinomaapudoma (NET)endometrial cancer (EC)cervical squamous cell carcinoma (CSCC)
Beyond the preview
Go deeper on NL-OMON53123.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53123.